InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

Closed (no longer recruiting)Last updated: 30 January 2024

APOLLO-1: This phase I/II trial is evaluating the combination of an oral drug (CBT-101) with two immunotherapy drugs (CBT-501 or Nivolumab) in patients with locally advanced or metastatic liver cancer or renal cell carcinoma (a type of kidney cancer)A Phase 1/2 Dose Escalation and Expansion Study of Combination CBT-501 or Nivolumab With CBT-101 in Locally Advanced or Metastatic Hepatocellular and Renal Cell Carcinoma

Clinical summary

Summary

This is a dose escalation and expansion trial, in which patients will be assigned to either Arm A or Arm B based on their cancer type. In Arm A, hepatocellular cancer patients will receive an intravenous dose (3mg/kg) of CBT-501 every two weeks and an oral dose (300 or 400mg) of CBT-101 twice daily continuously until documented disease progression, study discontinuation or withdrawal. In Arm B, renal cell carcinoma patients will receive an intravenous dose (3mg/kg or 240mg) of nivolumab every two weeks and an oral dose (300 or 400mg) of CBT-101 twice daily continuously until documented disease progression, study discontinuation or withdrawal. Please note: Arm A has now closed.

Conditions

This trial is treating patients with renal cell carcinoma (a type of kidney cancer).

Cancer

Urinary System Cancers Genitourinary

Age

People18+

Phase

I/II

Trial Acronym

APOLLO-1

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

CBT Pharmaceuticals (Australia) Pty Ltd.

Scientific Title

A Phase 1/2 Dose Escalation and Expansion Study of Combination CBT-501 or Nivolumab With CBT-101 in Locally Advanced or Metastatic Hepatocellular and Renal Cell Carcinoma

Eligibility

Inclusion

  1. Able to understand and comply with the study procedures, understand the risks involved in the study, and provide written informed consent.
  2. Men and women 18 years of age or older.
  3. Histologically confirmed advanced or metastatic hepatocellular carcinoma that progressed while receiving at least one previous line of systemic therapy, including sorafenib, or who are intolerant of or refused sorafenib treatment following progression on standard therapy including surgical and/or local regional therapies, or standard therapy considered ineffective, intolerable, or inappropriate or for which no effective standard therapy is available.
  4. Histologically confirmed advanced or metastatic renal cell carcinoma with clear cell component who received one or two prior lines of antiangiogenic therapy in addition to no more than three previous regimens of systemic therapy including cytokines and cytotoxic chemotherapy agents.
  5. Disease according to irRECIST that can be reliably and consistently followed.
  6. Documented disease progression during or after the last treatment regimen and within 6 months before study enrollment.
  7. Tumor amenable to tumor biopsy and subject agreeable to tumor biopsy at study entry and during therapy with study treatment.
  8. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  9. Acceptable organ function.

Exclusion

  1. History of severe hypersensitivity to mAbs, excipients of the APL-501, nivolumab, or APL-101.
  2. History of receiving treatment with any c-Met signaling pathway inhibitor (marketed or investigational agents).
  3. Prior therapy with anti-PD-1, anti-PD-L1, anti-PDL-2, or anti-CTLA-4 antibody (or any other antibody targeting T cell co-stimulation pathways).
  4. Unwilling to swallow orally administered medication whole.
  5. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter drug absorption (e.g., Crohn's, ulcerative colitis, active inflammatory bowel disease, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome).
  6. Documented and/or known history of human immunodeficiency virus (HIV) for HCC and RCC subjects, or historical seropositive results consistent with active infection for hepatitis C virus (HCV) or hepatitis B virus (HBV) (RCC only).
  7. HCC subjects receiving active antiviral therapy for HCV.
  8. Active co-infection with HBV and HCV.
  9. Active co-infection with HBV and hepatitis D virus.

Inclusion

  • You are able to swallow medication by mouth.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has spread to other parts of the body.

Exclusion

  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

+ Show non-recruiting hospitals

Closed hospitals

Completed hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

Speak with someone who has cancer clinical trial experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.

RAP

Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.